arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Anixa Biosciences Inc

ANIX
$3.44 ▲ +0.01 (+0.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anixa Biosciences Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -61.0%
FCF / Share
Trailing P/E
Price / Book 7.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$210.00K
— 0.0%
Net Income Profit after all expenses
$-10.93M
↑ +13.0%
Operating Margin Operating profit as % of sales
-10.2%
↑ +92.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 61 quarters